Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine

Vaccine

Volumn 31, Issue 26, 2013, Pages 2822-2827

  Yang, Chin Fen ^a   Wang, C Kathy ^a   Malkin, Elissa ^a   Schickli, Jeanne H ^a   Shambaugh, Cindy ^a   Zuo, Fengrong ^a   Galinski, Mark S ^a   Dubovsky, Filip ^a   Tang, Roderick S ^a  

^a MEDIMMUNE   (United States)

Author keywords

Immunogenicity; Respiratory syncytial virus (RSV); RSV F expression; Virus variants

Indexed keywords

INFLUENZA VACCINE; MEDI 534; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RSV F PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CLINICAL ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGENICITY; INFLUENZA A; INFLUENZA B; NOSE SMEAR; OPEN READING FRAME; PARAINFLUENZA VIRUS 3; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; TRANSCRIPTION TERMINATION; TRANSGENE; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; CATTLE; COHORT STUDIES; HUMANS; INFANT; PARAINFLUENZA VIRUS 3, BOVINE; PARAINFLUENZA VIRUS 3, HUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SEQUENCE ANALYSIS, DNA; TRANSGENES; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS SHEDDING;

EID: 84878393878     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.006     Document Type: Article

References (13)

1. Bernstein D.I., Malkin E., Abughali N., Falloon J., Yi T., Dubovsky F., et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012, 31(2):109-114.
2. Greenberg D.P., Walker R.E., Lee M.S., Reisinger K.S., Ward J.I., Yogev R., et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis 2005, 191(7):1116-1122.
3. Groothuis J.R., Hoopes J.M., Hemming V.G. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther 2011, 28:91-109.
4. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360(6):588-598.
5. Haller A.A., Miller T., Mitiku M., Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 2000, 74(24):11626-11635.
6. Karron R.A., Thumar B., Schappell E., Surman S., Murphy B.R., Collins P.L., et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 2012, 30(26):3975-3981.
7. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
8. Nelson CA, Tang RS, Stillman E. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells. Vaccine J, in press.
9. Piedra P.A., Jewell A.M., Cron S.G., Atmar R.L., Glezen W.P. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003, 21(24):3479-3482.
10. Roymans D., Koul A. Respiratory syncytial virus: a prioritized or neglected target?. Future Med Chem 2010, 2:1523-1527.
11. Schickli J.H., Dubovsky F., Tang R.S. Challenges in developing a pediatric RSV vaccine. Hum Vac 2009, 5(9):582-591.
12. Shinoff J.J., O'Brien K.L., Thumar B., Shaw J.B., Reid R., Hua W., et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008, 198(7):1007-1015.
13. Tang R.S., MacPhail M., Schickli J.H., Kaur J., Robinson C.L., Lawlor H.A., et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 2004, 78(20):11198-11207.